BioLife Solutions (NASDAQ:BLFS) issued its earnings results on Thursday. The medical equipment provider reported $0.04 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.04, Morningstar.com reports. The business had revenue of $5.46 million during the quarter, compared to the consensus estimate of $5.47 million. BioLife Solutions had a return on equity of 8.63% and a net margin of 10.42%. BioLife Solutions updated its FY 2019 guidance to EPS.
BioLife Solutions stock traded up $1.27 during mid-day trading on Friday, reaching $18.96. The stock had a trading volume of 3,235 shares, compared to its average volume of 155,449. BioLife Solutions has a fifty-two week low of $4.85 and a fifty-two week high of $26.35. The stock has a market capitalization of $327.27 million, a PE ratio of -89.17 and a beta of 1.65.
In other BioLife Solutions news, VP Todd Berard sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $12.12, for a total value of $36,360.00. Following the completion of the sale, the vice president now owns 37,583 shares of the company’s stock, valued at $455,505.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Greef Roderick De sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $17.23, for a total value of $172,300.00. Following the completion of the sale, the chief financial officer now directly owns 24,583 shares of the company’s stock, valued at approximately $423,565.09. The disclosure for this sale can be found here. Insiders sold 57,869 shares of company stock valued at $781,532 in the last three months. Insiders own 38.50% of the company’s stock.
A number of brokerages have weighed in on BLFS. BidaskClub upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a report on Friday, March 1st. ValuEngine upgraded BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 28th. Zacks Investment Research downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Janney Montgomery Scott upgraded BioLife Solutions to a “buy” rating and set a $5.00 target price for the company in a report on Thursday, December 20th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $17.75.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
Recommended Story: Derivative
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.